Inactive Instrument

Other languages Ampliphi Biosciences Corp OTC Bulletin Board

Equities

APHB

US03211P1030

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Mar. 21	Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	MT
Mar. 21	Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	23-10-30
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus	23-09-26
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-09-20
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-07-11
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors	23-07-11
Top Premarket Gainers	23-05-18
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-05-05
Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-15
Armata Pharmaceuticals Says Phase 1b/2a Trial of AP-PA02 Shows Drug 'Well-Tolerated' -- Shares Rise Pre-Bell	23-03-06
Armata Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis	23-03-06
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	22-12-22
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections	22-08-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ampliphi Biosciences Corp OTC Bulletin Board

Equities

APHB

US03211P1030

Other languages

Filters